Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion, Expanding Its Immunology and Rare Disease Portfolio

Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion, Expanding Its Immunology and Rare Disease Portfolio

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.

Biogen Inc. (Nasdaq: BIIB) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire all outstanding shares of Apellis for $41.00 per share in cash at closing, or approximately $5.6 billion. Apellis stockholders will also receive a nontransferable CVR for each Apellis share held, entitling the holder to receive two payments of $2 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE®. The addition of Apellis, a leader in advancing treatments for serious, complement-driven diseases, is expected to enhance Biogen’s short- and long-term revenue growth profile by adding two commercialized, differentiated immunology and rare disease medicines to its growth portfolio.

WilmerHale has represented Apellis since 2010 and acted as co-counsel to the company in the transaction.

The WilmerHale team was led by Hal Leibowitz, Andrew Bonnes, Stuart Falber and Jeffries Oliver-Li, and included partners Meghan Walsh, Fred Adam, Ciara Baker, Kirk Nahra, Bruce Manheim, Andrew Stauber, Molly Fox, Scott Lunin, Hartmut Schneider, and Steven Barrett, as well as Katherine Patterson, Jeannette Boot, Karen Velez, Jaclyn Schofield, and Skyler Dykes.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel